GSK abandons diversity targets following Trump pressure
British drugmaker GSK will no longer set diversity targets, it said on Thursday, as it became the latest company to scale back or abandon such goals in response to the U.S. president's opposition to them.
Canada purchases 500,000 doses of GSK's vaccine for bird flu
The Public Health Agency of Canada said on Wednesday it has secured an initial supply of 500,000 doses of GSK's bird flu vaccine to protect individuals most at risk.
GSK's Strong Performance: Why I'm Upgrading To 'Strong Buy'
GSK's revenue and EPS exceeded my expectations and those of analysts, thanks to the strong performance of its oncology and HIV franchises. So, Ojjaara/Omjjara sales amounted to $150 million in the fourth quarter of 2024, more than tripling year-on-year. While sales of the HIV therapy called Cabenuva also did not disappoint, totaling $396 million, up 23.8% quarter-on-quarter.
Ken Griffin's Citadel Places Big Short Bet Against GSK - Here's What It Means for Investors
Ken Griffin 's hedge fund Citadel has placed a £305 million ($390 million) short bet against GSK PLC GSK, marking the largest wager against the UK pharma giant in over a decade, reported the Financial Times.
GSK meningitis jab bags approval by FDA
GSK PLC has bagged approval for its Penmenvy meningitis vaccine by the US Food and Drug Administration. Designed to target five major serogroups of meningitis-causing Neisseria meningitidis bacteria, GSK on Monday said the jab had been green lit for 10 to 25 year olds.
US FDA approves GSK's combo meningococcal vaccine
The U.S. Food and Drug Administration (FDA) approved GSK's combination vaccine to protect against meningococcal infection for use in individuals aged 10 through 25 years, the company said on Saturday.
Hedge Fund Citadel takes short position in GSK, FT reports
Hedge fund Citadel has made a 305 million pound ($384.5 million) bet against drugmaker GSK , the Financial Times reported on Friday.
India's GlaxoSmithKline Pharma reports higher profit on strong demand for respiratory drugs
India's GlaxoSmithKline Pharmaceuticals reported a higher adjusted third-quarter profit on Friday, led by sustained demand for its respiratory drugs and antibiotic Augmentin.
GSK's speciality medicines arm gets the seal of approval from UK broker
Shore Capital has reiterated its ‘buy' rating on GSK PLC (LSE:GSK, NYSE:GSK), highlighting the strength of its speciality medicines business as the driving force behind future growth. Despite challenges in the vaccines segment, the investment bank believes GSK remains well-positioned to meet its post-demerger growth targets.
Bear Of The Day: GSK PLC (GSK)
Healthcare stock investors have been feeling rather sick about the potential changes the Trump Administration may bring.
GSK Reported Strong Earnings, So I Reiterate My Strong Buy
GSK's 2024 results are strong, with a promising shift toward specialty medicines, particularly in HIV, respiratory conditions, and cancer, driving long-term growth. Key drugs Blenrep and Depemokimab show significant potential, with impressive Phase 3 results, expected to boost GSK's revenues by an extra £7 billion. Despite some IRA and clinical trial risks, GSK's focus on specialty medicines and stable margins make it a compelling blue-chip investment, currently undervalued.
GSK prelims get City thumbs up as investment banks upgrade
UBS has raised its target price for GSK PLC (LSE:GSK, NYSE:GSK) from £15.80 to £16, following a better-than-expected full-year earnings report and a focus on improving shareholder returns. The pharmaceutical company's 2025 guidance suggests 3-5% sales growth, despite anticipated weakness in vaccine sales and a £400-500 million impact from U.S.
